How is polycythemia vera distinguished from other causes of a high hemoglobin?

It is a clonal disease usually marked by a JAK2 mutation and a characteristically low serum erythropoietin, which separates it from secondary erythrocytosis driven by hypoxia or erythropoietin excess, where erythropoietin is normal or high.

Why does polycythemia vera raise the risk of clots?

The increased red-cell mass raises blood viscosity and, combined with qualitative changes in platelets and white cells, predisposes to both arterial and venous thrombosis, which is the disease's main early complication.

Polycythemia Vera

Polycythemia vera is a myeloproliferative neoplasm in which a clonal stem-cell mutation drives sustained overproduction of red cells, and often white cells and platelets, raising the red-cell mass and blood viscosity. Almost all cases carry a JAK2 mutation, and the disease's chief hazards are thrombosis and, over the long term, progression to myelofibrosis or acute leukemia.

Definition

Polycythemia vera is a Philadelphia-chromosome-negative myeloproliferative neoplasm characterized by clonal, JAK2-mutation-driven overproduction of erythrocytes (with frequent granulocytosis and thrombocytosis) and an elevated red-cell mass, carrying an increased risk of thrombosis and of late transformation to myelofibrosis or acute myeloid leukemia.

Scope

This entry describes polycythemia vera as a disease entity: its molecular driver, the resulting increase in red-cell mass, its clinical hazards, and how it is classified. It is a reference and educational topic and does not provide treatment thresholds, target counts, or management advice for individual patients.

Key concepts

Erythrocytosis and elevated red-cell mass
JAK2 V617F and exon 12 mutations
Low serum erythropoietin
Increased blood viscosity
Thrombosis risk
Transformation to post-PV myelofibrosis and acute leukemia
Distinction from secondary erythrocytosis

Mechanisms

In nearly all patients a somatic JAK2 mutation, most often V617F and in the remainder an exon 12 variant, constitutively activates JAK-STAT signalling in hematopoietic progenitors, rendering them hypersensitive to erythropoietin and other cytokines and driving erythroid overproduction independent of normal feedback (Kralovics, 2005). The expanded red-cell mass raises whole-blood viscosity and, together with qualitative platelet and leukocyte changes, predisposes to arterial and venous thrombosis. Because the drive is intrinsic rather than hypoxia-mediated, serum erythropoietin is characteristically low, distinguishing the disease from secondary erythrocytosis. Over years the clone may evolve toward a spent, fibrotic phase or to acute leukemia (Arber, 2016).

Clinical relevance

Polycythemia vera is a leading cause of true clonal erythrocytosis and an important consideration when a raised hemoglobin or hematocrit is found, particularly alongside thrombosis at unusual sites. This entry explains the disease and its natural history for reference; it does not give hematocrit targets or treatment recommendations for individual patients.

Epidemiology

Polycythemia vera is one of the classic myeloproliferative neoplasms, with an incidence on the order of one to two cases per hundred thousand people per year and a median age at diagnosis around the sixties; it is slightly more common in men. Thrombosis is the major early cause of morbidity, while transformation to myelofibrosis or acute leukemia accounts for much of the late mortality.

Evidence & guidelines

The World Health Organization criteria combine an elevated hemoglobin, hematocrit, or red-cell mass with a JAK2 mutation and characteristic marrow findings (Arber, 2016). A landmark randomized trial showed that maintaining a lower hematocrit target was associated with fewer cardiovascular events, establishing tight hematocrit control as a central principle of care (Marchioli, 2013), and a randomized trial of the JAK inhibitor ruxolitinib demonstrated benefit in patients resistant to or intolerant of hydroxyurea (Vannucchi, 2015).

History

The disease was described by Louis Henri Vaquez in 1892 and further characterized by William Osler, and for a century it was defined clinically by erythrocytosis with a raised red-cell mass. Its modern molecular understanding arrived in 2005 with the identification of the JAK2 V617F mutation in the great majority of cases, which transformed both diagnosis and classification (Kralovics, 2005). Subsequent randomized trials refined management principles such as hematocrit control and JAK inhibition (Marchioli, 2013; Vannucchi, 2015).

Debates

How aggressively should the hematocrit be controlled?: A randomized comparison found fewer cardiovascular events with a stricter hematocrit target, supporting tight control, though the optimal threshold across patient subgroups remains a matter of ongoing study.

Key figures

Louis Henri Vaquez
William Osler
Robert Kralovics
Radek Skoda
Roberto Marchioli

Seminal works

kralovics-2005
marchioli-2013
vannucchi-2015

Frequently asked questions

How is polycythemia vera distinguished from other causes of a high hemoglobin?: It is a clonal disease usually marked by a JAK2 mutation and a characteristically low serum erythropoietin, which separates it from secondary erythrocytosis driven by hypoxia or erythropoietin excess, where erythropoietin is normal or high.
Why does polycythemia vera raise the risk of clots?: The increased red-cell mass raises blood viscosity and, combined with qualitative changes in platelets and white cells, predisposes to both arterial and venous thrombosis, which is the disease's main early complication.